S. Brunet

发表

Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.

M. Díaz-Beyá, L. Zamora, M. Calabuig, 2022, Leukemia research.

Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantation

H. Prentice, X. Troussard, P. Ljungman, 1995, Stem cells.

Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group.

H. Tilg, P. Biron, P. Ljungman, 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.

A. López-Guillermo, F. Bosch, E. Montserrat, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.

J. Garcia-conde, J. Hernández-Rivas, A. Oriol, 1998, Haematologica.

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

J. Esteve, L. Escoda, E. Vellenga, 2018, Leukemia.

Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.

P. Bolufer, E. Barragán, M. Sanz, 2000, Haematologica.

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

J. Esteve, L. Escoda, M. Tormo, 2007, Leukemia.

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

J. Esteve, E. Montserrat, J. Garcia-conde, 2001, The hematology journal : the official journal of the European Haematology Association.

Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation.

P. Ljungman, L. Verdonck, A. Goldstone, 1994, Leukemia & lymphoma.

Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells

N. Villamor, D. Colomer, J. Nomdedéu, 2003, Leukemia.

Quantitative Detection of AML1-ETO Rearrangement by Real-Time RT-PCR Using Fluorescently Labeled Probes

P. Bolufer, E. Barragán, I. Moreno, 2001, Leukemia & lymphoma.

Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols.

J. Esteve, Marcos González, E. Vellenga, 2006 .

Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.

J. Esteve, A. Aventín, S. Brunet, 2012, Leukemia research.

Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.

A. López-Guillermo, F. Bosch, E. Montserrat, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.

P. Bolufer, T. Gómez, M. González, 2000, Haematologica.